HK1210191A1 - Methods for the manufacture of proteolytically processed polypeptides - Google Patents
Methods for the manufacture of proteolytically processed polypeptidesInfo
- Publication number
- HK1210191A1 HK1210191A1 HK15110930.5A HK15110930A HK1210191A1 HK 1210191 A1 HK1210191 A1 HK 1210191A1 HK 15110930 A HK15110930 A HK 15110930A HK 1210191 A1 HK1210191 A1 HK 1210191A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- manufacture
- methods
- proteolytically processed
- processed polypeptides
- polypeptides
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/073283 WO2014079495A1 (fr) | 2012-11-21 | 2012-11-21 | Procédés pour réaliser des polypeptides traités de manière protéolytique |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1210191A1 true HK1210191A1 (en) | 2016-04-15 |
Family
ID=47216287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110930.5A HK1210191A1 (en) | 2012-11-21 | 2015-11-05 | Methods for the manufacture of proteolytically processed polypeptides |
Country Status (15)
Country | Link |
---|---|
US (4) | US10087432B2 (fr) |
JP (3) | JP6156954B2 (fr) |
KR (4) | KR102083371B1 (fr) |
CN (4) | CN104870468B (fr) |
AR (3) | AR093578A1 (fr) |
AU (2) | AU2012395188B2 (fr) |
BR (2) | BR112015003591B1 (fr) |
CA (2) | CA3062150C (fr) |
HK (1) | HK1210191A1 (fr) |
IN (1) | IN2015DN01449A (fr) |
MX (2) | MX363788B (fr) |
RU (2) | RU2673910C2 (fr) |
TW (5) | TW201439322A (fr) |
UA (2) | UA111795C2 (fr) |
WO (2) | WO2014079495A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10792344B2 (en) * | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
CA3062150C (fr) * | 2012-11-21 | 2021-12-21 | Ipsen Bioinnovation Limited | Procedes pour realiser des polypeptides traites de maniere proteolytique |
WO2015088477A1 (fr) * | 2013-12-09 | 2015-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Substrats peptidiques identifiables par la neurotoxine botulique de type e |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
CA2949653C (fr) * | 2014-05-29 | 2019-12-17 | Procell Therapeutics Inc. | Nouveau peptide penetrant une cellule, conjugue associe comportant la toxine botulinum et utilisation associee |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
EP3263710A1 (fr) * | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production de neurotoxines clostridiales activées |
JP2019526611A (ja) | 2016-09-13 | 2019-09-19 | アラーガン、インコーポレイテッドAllergan,Incorporated | 非タンパク質クロストリジウム毒素組成物 |
KR20200070310A (ko) * | 2017-10-13 | 2020-06-17 | 위스콘신 얼럼나이 리서어치 화운데이션 | 보툴리눔 신경독 a 서브타입 6 및 약리학적 사용 방법 |
EP3752128A1 (fr) * | 2018-02-16 | 2020-12-23 | Bontana Therapies Gmbh | Neurotoxine botulique reposant sur un acide nucléique, pour application thérapeutique |
KR102246906B1 (ko) * | 2019-04-29 | 2021-04-30 | 주식회사 바이오셀트란 | 피부 또는 세포 투과능이 우수한 피부주름 방지 또는 개선용 화장료 조성물 |
GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
EP4121100A2 (fr) | 2020-03-16 | 2023-01-25 | Ipsen Biopharm Limited | Traitement de la spasticité des membres |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
CA3231083A1 (fr) | 2021-09-16 | 2023-03-23 | Nicolae GRIGORE | Bont/a modifiee destinee a etre utilisee dans le traitement de la dystonie cervicale |
KR20240067100A (ko) | 2021-09-23 | 2024-05-16 | 입센 바이오팜 리미티드 | 대상체의 안검 근육에 이환된 장애의 치료에 사용하기 위한 변형된 bont/a |
GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
CA3234608A1 (fr) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Traitement de la douleur |
GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7227010B2 (en) * | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US8153397B2 (en) * | 1993-09-21 | 2012-04-10 | The United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
WO1996005222A1 (fr) * | 1994-08-08 | 1996-02-22 | Wisconsin Alumni Research Foundation | Procede de purification et compositions pharmaceutiques contenant la neurotoxine botulinique de type g |
US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
DE19856897A1 (de) | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
EP1700918B1 (fr) * | 1999-08-25 | 2014-01-15 | Allergan, Inc. | Neurotoxines recombinantes activables |
US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
US7740868B2 (en) * | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US7402556B2 (en) | 2000-08-24 | 2008-07-22 | Medarex, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
TW526437B (en) * | 2001-08-08 | 2003-04-01 | Macronix Int Co Ltd | Photolithography rework analysis method and system |
JP2005538954A (ja) * | 2002-05-31 | 2005-12-22 | トーマス・ジェファーソン・ユニバーシティ | 分子の経上皮輸送用組成物及び方法 |
US20040018589A1 (en) * | 2002-07-25 | 2004-01-29 | Jun Zhong | Method for producing biologically active botulinum neurotoxins through recombinant DNA technique |
CA2492883C (fr) * | 2002-08-01 | 2012-10-02 | James D. Marks | Anticorps monoclonaux therapeutiques qui neutralisent les neurotoxines botuliques |
WO2004031355A2 (fr) * | 2002-10-01 | 2004-04-15 | University Of Maryland | Methodes permettant d'identifier des inhibiteurs de neurotoxines botuliques |
US7341843B2 (en) * | 2003-04-11 | 2008-03-11 | Allergan, Inc. | Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
US20080171347A1 (en) * | 2003-04-11 | 2008-07-17 | Atassi M Zouhair | Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides |
US20050169942A1 (en) * | 2003-10-07 | 2005-08-04 | Allergan, Inc. | Novel DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain for production of therapeutics |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US20080057575A1 (en) * | 2004-08-04 | 2008-03-06 | Allergan, Inc. | Optimizing Expression of Active Botulinum Toxin Type A |
JP5089388B2 (ja) * | 2004-09-01 | 2012-12-05 | アラーガン、インコーポレイテッド | 分解可能なクロストリジウム毒素 |
DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
DE102005002978B4 (de) * | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
JP2008535486A (ja) * | 2005-03-15 | 2008-09-04 | アラーガン、インコーポレイテッド | クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素 |
US7465457B2 (en) * | 2005-04-14 | 2008-12-16 | Wisconsin Alumni Research Foundation | Method for preparing botulinum neurotoxin type A light chain |
DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
DK2154151T3 (da) * | 2005-09-19 | 2011-09-05 | Allergan Inc | Clostridiumtoksinaktiverbare clostridiumtoksiner |
US9072735B2 (en) | 2005-10-03 | 2015-07-07 | Yong Qian | Proteinases destroy cancer tumor's solid structure and kill cancer cells locally |
US7464917B2 (en) * | 2005-10-07 | 2008-12-16 | Appiled Materials, Inc. | Ampoule splash guard apparatus |
DE102005051789B4 (de) * | 2005-10-28 | 2014-08-07 | Toxogen Gmbh | Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen |
GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
JP2009543557A (ja) * | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力およびクロストリジウム毒素標的細胞に対する変化したターゲティング活性を有する改変クロストリジウム毒素 |
KR100677871B1 (ko) * | 2006-09-11 | 2007-02-02 | 주식회사 메가젠 | 골충진재 성형 장치 및 골충진재 성형 방법 |
CA2693958A1 (fr) * | 2007-06-14 | 2008-12-18 | Emergent Biosolutions, Inc. | Peptides chimiquement modifies presentant une meilleure immunogenicite |
EP2178905B1 (fr) * | 2007-07-26 | 2013-11-06 | Allergan, Inc. | Procédés d'activation de toxines clostridiales |
EP2023327A1 (fr) * | 2007-07-27 | 2009-02-11 | Foxboro Eckardt Gmbh | Contrôleur de tension de fonctionnement et procédé pour la commande d'un contrôleur de tension de fonctionnement |
SG185338A1 (en) * | 2007-10-23 | 2012-11-29 | Allergan Inc | Methods of treating urogenital-neurological disorders using modified clostridial toxins |
JP2011514307A (ja) * | 2007-10-23 | 2011-05-06 | アラーガン、インコーポレイテッド | 改変クロストリジウム毒素を用いる慢性神経性炎症の治療方法 |
EP2271670B1 (fr) * | 2008-03-14 | 2014-09-03 | Allergan, Inc. | Essais d activité de sérotype a de toxine du botulisme à base immunitaire |
US9000131B2 (en) * | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
WO2010085473A1 (fr) * | 2009-01-20 | 2010-07-29 | Trustees Of Tufts College | Procédés pour l'administration de toxines ou de parties enzymatiquement actives correspondantes |
CN102325792B (zh) * | 2009-02-19 | 2018-01-09 | 莫茨制药有限及两合公司 | 用于生产高纯度神经毒素的手段和方法 |
RU2011139364A (ru) * | 2009-03-13 | 2013-04-20 | Аллерган, Инк. | Клетки для применения в иммунологических тестах на активность ботулинического токсина серотипа а |
ES2647243T3 (es) * | 2009-04-27 | 2017-12-20 | Merz Pharma Gmbh & Co. Kgaa | Medios y métodos para la determinación de la cantidad de polipéptido Neurotoxina y de sus actividades catalíticas y proteolíticas |
US20100303783A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases |
US20100303757A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases |
WO2011000929A1 (fr) * | 2009-07-02 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxines présentant une activité biologique raccourcie |
EP2488868B1 (fr) * | 2009-10-16 | 2016-03-30 | BioMadison, Inc. | Analyse par transfert d'énergie de résonance utilisant, comme substrat, une fraction de synaptobrévine |
US10246492B2 (en) * | 2009-10-16 | 2019-04-02 | Biomadison, Inc. | Botulinum assay with synaptobrevin substrate moiety |
RU2012129557A (ru) * | 2009-12-16 | 2014-01-27 | Аллерган, Инк. | МОДИФИЦИРОВАННЫЕ ТОКСИНЫ Clostridial, СОДЕРЖАЩИЕ ИНТЕГРИРОВАННЫЙ САЙТ-СВЯЗЫВАЮЩИЙ ДОМЕН ПРОТЕАЗНОГО РАСЩЕПЛЕНИЯ |
US20130245227A1 (en) * | 2010-01-15 | 2013-09-19 | Allergan, Inc. | Methods of activating clostridial toxins |
SI2684890T1 (sl) * | 2010-01-25 | 2016-10-28 | Allergan, Inc. | Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko |
AT511002A1 (de) * | 2011-02-08 | 2012-08-15 | Univ Innsbruck | Verfahren zur verformung von cellulosecarbamat und produkte, die nach diesem verfahren hergestellt werden |
WO2012112432A1 (fr) * | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Méthodes d'inhibition de la formation aberrante de vaisseaux sanguins à l'aide d'endopeptidases reciblées sur des opioïdes |
US20120207734A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases |
GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
PT2677029T (pt) * | 2011-05-19 | 2017-08-11 | Ipsen Bioinnovation Ltd | Métodos para o fabrico de polipéptidos processados proteoliticamente |
RU2646110C2 (ru) * | 2011-11-09 | 2018-03-01 | Мерц Фарма Гмбх Унд Ко. Кгаа | Нейротоксины, проявляющие укороченную биологическую активность |
WO2013131991A1 (fr) * | 2012-03-07 | 2013-09-12 | Merz Pharma Gmbh & Co. Kgaa | Moyens et procédés pour déterminer l'activité d'une neurotoxine basée sur une luciférase modifiée |
KR101729710B1 (ko) * | 2012-04-09 | 2017-04-24 | 서울대학교산학협력단 | 물에 안정하게 분산되는 멜라닌 나노입자를 포함하는 핵자기 공명 영상 조영제 |
US9598685B2 (en) * | 2012-05-30 | 2017-03-21 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
US20150232828A1 (en) * | 2012-08-20 | 2015-08-20 | Merz Pharma Gmbh & Co. Kgaa | Method for the manufacturing of recombinant proteins harbouring an n-terminal lysine |
CA3062150C (fr) * | 2012-11-21 | 2021-12-21 | Ipsen Bioinnovation Limited | Procedes pour realiser des polypeptides traites de maniere proteolytique |
WO2014079497A1 (fr) * | 2012-11-22 | 2014-05-30 | Drugs For Neglected Diseases Initiative (Dndi) | Procédé de préparation de dérivés phényloxyméthyl-nitro-imidazole et leur utilisation |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
JP7017932B2 (ja) * | 2014-12-09 | 2022-02-09 | ニューヨーク・ユニバーシティ | クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法 |
EP3270951B1 (fr) * | 2015-03-16 | 2020-09-09 | California Institute of Technology | Agents de capture spécifiques de la neurotoxine botulique, compositions et méthodes d'utilisation et de préparation associées |
GB201505306D0 (en) * | 2015-03-27 | 2015-05-13 | Ipsen Biopharm Ltd | Chimeric polypeptides |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
SG11201809903WA (en) * | 2016-05-16 | 2018-12-28 | Harvard College | Method for purification and activation of botulinum neurotoxin |
UA125965C2 (uk) * | 2016-07-08 | 2022-07-20 | Чілдренс Медікал Сентр Корпорейшн | Новий ботулінічний нейротоксин та його похідні |
-
2012
- 2012-11-21 CA CA3062150A patent/CA3062150C/fr active Active
- 2012-11-21 MX MX2015002390A patent/MX363788B/es active IP Right Grant
- 2012-11-21 US US14/423,222 patent/US10087432B2/en active Active
- 2012-11-21 CN CN201280075874.2A patent/CN104870468B/zh active Active
- 2012-11-21 AU AU2012395188A patent/AU2012395188B2/en active Active
- 2012-11-21 BR BR112015003591-4A patent/BR112015003591B1/pt active IP Right Grant
- 2012-11-21 KR KR1020157004071A patent/KR102083371B1/ko active IP Right Grant
- 2012-11-21 UA UAA201502409A patent/UA111795C2/uk unknown
- 2012-11-21 WO PCT/EP2012/073283 patent/WO2014079495A1/fr active Application Filing
- 2012-11-21 JP JP2015535999A patent/JP6156954B2/ja active Active
- 2012-11-21 RU RU2015107240A patent/RU2673910C2/ru active
- 2012-11-21 CA CA2880897A patent/CA2880897C/fr active Active
- 2012-11-21 CN CN202010161444.9A patent/CN111454931A/zh active Pending
- 2012-11-21 KR KR1020187018705A patent/KR20180077343A/ko not_active Application Discontinuation
- 2012-11-21 KR KR1020177012803A patent/KR102083373B1/ko active IP Right Grant
-
2013
- 2013-11-21 AR ARP130104298A patent/AR093578A1/es active IP Right Grant
- 2013-11-21 KR KR1020157016356A patent/KR20150085844A/ko not_active Application Discontinuation
- 2013-11-21 WO PCT/GB2013/053072 patent/WO2014080206A1/fr active Application Filing
- 2013-11-21 CN CN201380060742.7A patent/CN104797595B/zh active Active
- 2013-11-21 JP JP2015543521A patent/JP2015536654A/ja active Pending
- 2013-11-21 TW TW102142485A patent/TW201439322A/zh unknown
- 2013-11-21 TW TW107123545A patent/TW201839134A/zh unknown
- 2013-11-21 CN CN202010771933.6A patent/CN112048009A/zh active Pending
- 2013-11-21 TW TW107123543A patent/TW201839133A/zh unknown
- 2013-11-21 BR BR112015010550A patent/BR112015010550A8/pt not_active Application Discontinuation
- 2013-11-21 UA UAA201506009A patent/UA117231C2/uk unknown
- 2013-11-21 TW TW107123546A patent/TWI713862B/zh active
- 2013-11-21 RU RU2015124069A patent/RU2015124069A/ru not_active Application Discontinuation
- 2013-11-21 TW TW107123542A patent/TWI709649B/zh active
- 2013-11-21 MX MX2015006324A patent/MX2015006324A/es unknown
-
2015
- 2015-02-20 IN IN1449DEN2015 patent/IN2015DN01449A/en unknown
- 2015-11-05 HK HK15110930.5A patent/HK1210191A1/xx unknown
-
2017
- 2017-08-30 AU AU2017221793A patent/AU2017221793B2/en active Active
-
2018
- 2018-08-20 US US16/105,120 patent/US10808236B2/en active Active
- 2018-11-05 JP JP2018208320A patent/JP2019030333A/ja active Pending
-
2020
- 2020-02-06 AR ARP200100322A patent/AR118019A2/es unknown
- 2020-07-14 US US16/928,107 patent/US11441141B2/en active Active
-
2022
- 2022-07-15 US US17/812,800 patent/US20230015772A1/en active Pending
- 2022-11-09 AR ARP220103075A patent/AR127620A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1210191A1 (en) | Methods for the manufacture of proteolytically processed polypeptides | |
HK1206635A1 (en) | Modified polynucleotides for the production of proteins | |
PL2677029T3 (pl) | Sposoby wytwarzania poddanych obróbce proteolitycznej polipeptydów | |
HK1206612A1 (en) | Modified polynucleotides for the production of secreted proteins | |
SG10201703051WA (en) | Compounds and methods for the production of suckerin and uses thereof | |
HK1204667A1 (en) | Method for the production of solid surfaces for construction | |
IL245474A0 (en) | Process for the preparation of 5-fluoro-1h-pyrazoles | |
HK1205097A1 (en) | Process for the production of methylbutinol | |
PL399420A1 (pl) | Sposób wytwarzania dihydrochalkonu | |
IL245476B (en) | Process for the preparation of 5-fluoro-1h-pyrazoles | |
HUE040552T2 (hu) | Eljárás rendkívül tiszta TDI-trimerizátumok elõállítására | |
IL236450A0 (en) | Process for the preparation of 5-fluoro-h1-pyrazoles | |
PL399419A1 (pl) | Sposób wytwarzania 4-metoksydihydrochalkonu | |
PL399418A1 (pl) | Sposób wytwarzania 4-metoksydihydrochalkonu | |
PL399421A1 (pl) | Sposób wytwarzania dihydrochalkonu | |
HUP1200171A1 (hu) | Módszerek polipeptidek elõállítására | |
HK1210225A1 (en) | Procedure for the production of tiacumicin | |
EP2938587A4 (fr) | Particules de céramique et procédé d'élaboration associé | |
IL229326A (en) | Process for making n-iodine-affluent | |
HK1212315A1 (en) | Silica-based structurants and processes for making thereof | |
ZA201405824B (en) | Process for the preparation of substituted phenylpropanones | |
IL246188B (en) | A process for the preparation of tiacomycin | |
PL2934428T3 (pl) | Sposób zwiększania wytrzymałości ceramik | |
HUP1200675A2 (en) | Process for the preparation of pyrimidinyl-piperazines | |
GB201202060D0 (en) | Novel compounds and methods for their production |